GLP-1激战正酣:有国产药获批临床,有跨国药企半途中止

中国制药网
Sep 09

在GLP-1这条赛道上,竞争正愈演愈烈,与此同时,有人获得新进展,有人选择半途中止。9月9日早间, 四环医药 在港交所公告,集团旗下非全资附属公司惠升生物制药股份有限公司自主研发的胰高血糖素样肽-1受体(GLP-1R)╱胰高血糖素受体(GCGR)双靶点激动剂 创新药 P052注射液新药临床试验申请获得国家药监局药品审评中心默示许可,用于治疗2型糖尿病、超重或肥胖症。据介绍,P052注射液不仅可以...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10